INVESTIGATION REMINDER The Schall Law Firm Announces it is Investigating Claims Against Adverum Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm

Nachrichtenquelle: Business Wire (engl.)
26.02.2020, 15:30  |  143   |   |   

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (“Adverum” or “the Company”) (NASDAQ: ADVM) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Adverum issued a press release detailing clinical data from the OPTIC Phase 1 clinical trial of the Company’s product ADVM-022 for the treatment for wet age-related macular degeneration on September 12, 2019. As part of this release, the Company admitted that patients taking ADVM-022 suffered a significant loss of vision. Based on this news, shares of Adverum fell by 50% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Adverum Biotechnologies Aktie jetzt ab 0€ handeln - auf Smartbroker.de



Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel